REGN Insider Buying & Government Contracts (2026)

REGN insider buying and selling over the past year

Insiders at REGENERON PHARMACEUTICALS, INC. only sold stock in the open market over the past year: 8 Form 4 sales totaling $9.32M, against no open-market purchases.

Most of the selling was pre-scheduled: 6 of the 8 sales (75.0%) were flagged as Rule 10b5-1 plan trades, which are set up in advance and say less about an insider's current view than discretionary sales. Activity clustered in 2026-02 (3 trades) and 2025-11 (2 trades); the latest filing in this window is dated 2026-03-02. The average open-market sale price was $713.72; the last close of $790.74 is 10.8% above that level, so sellers left upside on the table. The single largest trade was a sale of 6,500 shares worth $4.25M on 2025-10-29. Since the most recent filing the stock has moved -0.0%, from $790.81.

Where REGN trades relative to its one-year range

REGENERON PHARMACEUTICALS, INC. closed at $790.74 on 2026-10-16, inside a one-year range of $575.69 to $852.03. That puts the stock in the middle of its range, at 77.8% of the distance from low to high. Over one year the share price moved +38.9%, and over roughly three months +16.9%. Average daily volume over the last month was about 789,090 shares.

Across 137 companies in the same SEC industry group (SIC 28) with a full year of prices in Gemral Edge, the median one-year return was +12.0%. REGN is ahead of that median and beat 77% of that peer group on this measure.

Members of Congress who traded REGN

STOCK Act disclosures show 21 trades in REGN by 11 members of Congress over five years (8 purchases, 13 sales), most recently on 2026-05-15. The most active traders were Josh Gottheimer (D-NJ), 3 trades; Julie Johnson (D-TX), 3 trades; Robert P. Bresnahan, Jr. (R-PA), 3 trades; Tommy Tuberville (R-AL), 3 trades; Byron Donalds (R-FL), 2 trades.

By party the trades split 11 by Republicans, 10 by Democrats; by chamber, 17 from the House, 4 from the Senate.

REGENERON PHARMACEUTICALS, INC. federal contract exposure

Federal procurement records resolve 1 prime award actions to REGENERON PHARMACEUTICALS, INC., worth $280.50M across 1 agencies. Department of Health and Human Services accounts for 100.0% of that value ($280.50M), so revenue from this channel depends heavily on one buyer.

REGN lobbying disclosures

REGENERON PHARMACEUTICALS, INC. appears in 3 Lobbying Disclosure Act filings between 2018 and 2018, with $380.0K in reported lobbying spend.

Compare REGN with indexed peers from the same industry group

These peers have full Gemral Edge dossiers and the closest one-year price move to REGN:

• BMY one-year return +37.7%
• DOW one-year return +36.7%
• KVUE one-year return +34.0%
• JNJ one-year return +33.0%
• GILD one-year return +32.5%

Sources and method

Every figure above is computed from public filings stored in Gemral Edge, not estimated. Insider figures count only open-market purchases and sales reported on SEC Form 4; option exercises, grants and gifts are excluded because they do not reflect a decision to buy or sell at market prices.

• SEC EDGAR Form 4 (edge_insider_trades, codes P/S open-market only) — as of 2026-03-02
• edge_prices_eod (end-of-day close) — as of 2026-10-16
• House PTR / Senate eFD disclosures (edge_congress_trades) — as of 2026-05-15
• FPDS / USAspending (edge_contracts, tier-1 resolved) — as of 2026-09-25
• Senate LDA filings (edge_lobbying_filings)

REGN data questions

Are REGN insiders buying or selling stock?

Insiders at REGENERON PHARMACEUTICALS, INC. only sold stock in the open market over the past year: 8 Form 4 sales totaling $9.32M, against no open-market purchases.

What is the one-year price range for REGN?

Based on end-of-day closes through 2026-10-16, REGN traded between $575.69 and $852.03, last closing at $790.74.

Has any member of Congress traded REGN stock?

Yes. 11 members disclosed 21 trades in REGN over five years; the most recent disclosed trade date is 2026-05-15.